MorphoSys to Start Share Buy-Back Program

MorphoSys AG /
MorphoSys to Start Share Buy-Back Program
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today the
decision to repurchase its own shares on the stock market. Following approval by
the Company´s Supervisory Board, the Board of Management of MorphoSys AG has
resolved to acquire up to 100,000 MorphoSys shares over the stock market during
the time period from April 1, 2012 to April 30, 2012. The shares will be used to
implement the Company´s long-term incentive program 2012 for its management.

The relevant conditions of the shareholders´ resolutions passed in the ordinary
shareholders´ meeting 2011 of MorphoSys AG on the authorization to acquire and
to use its own shares shall apply. The purchase price paid per share may not be
more than 10 % higher or 20 % lower than the Company´s share price determined by
the opening auction in the Xetra trading system on the day of trading. On the
basis of the current share price (status: March 30, 2012), this would amount to
around EUR 1.76 million or up to 0.4% of the share capital.

The buy-back is to be handled independently of and uninfluenced by the Company
through an appointed bank in compliance with the safe-harbor provisions.

MorphoSys will provide regular information on the progress of the share buy-back
program on the Company´s website www.morphosys.com.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
Company´s AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more than
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer´s disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is focused
on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt
Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit
http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and arYla® are
registered trademarks of MorphoSys AG. Ylanthia® and 100 billion high
potentialsTM are trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company´s
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

[e-mail]

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX, CDAX, Prime All Share, TECH All Share, HDAX, MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Media Release:
http://hugin.info/130295/R/1599183/504495.pdf

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1599183]

Wertpapiere des Artikels:
DE0006632003